AMSBIO, a provider of cutting-edge products and services for accelerating stem cell research, has sponsored two aspiring life scientists to attend and present posters at the recent ISSCR 2023 conference in Boston, USA. Whilst the original award was for one researcher, AMSBIO doubled the fund and awarded two grants based on the high quality of the entries.
Krystyna Joyce, AMSBIO’s marketing manager, said “The entries were so impressive that we ended up sponsoring two winners instead of one: Kerstin Filippi, a doctoral student at the University of Bonn researching in BAG3-associated muscle…
One Nucleus Partner, Agility Life Sciences, has announced a collaborative services agreement with Inaphaea BioLabs. Claire Thompson, CEO of Agility, commented: "This will enable our clients to take the next steps in their development programmes by testing their prototype formulations in the Inaphaea cell based studies. We believe this will be beneficial to both companies as well as to our clients, creating a more comprehensive scientific environment, and accelerating development timelines."
Progressive plans for the next phase of Manchester Science Park’s masterplan development have been approved by Manchester City Council. The scheme will see Bruntwood SciTech, a 50:50 joint venture between Bruntwood and Legal & General, deliver a £60m redevelopment of the Park’s existing Greenheys building, bringing forward 131,000 sq ft of highly specialist world-class lab space.
The redevelopment by the UK’s leading property provider dedicated to the growth of the science and technology sector forms the third phase of Bruntwood SciTech’s masterplan to grow the science and technology hub…
Astex Expands Drug Discovery Collaboration With MSD
Cambridge, UK, 8 August 2023, Astex Pharmaceuticals (UK) (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, today announced an exclusive worldwide research collaboration and license agreement with MSD (Merck & Co., Inc., Rahway, N.J., USA). The goal of the collaboration is to identify small molecule candidates with activity towards a tumour suppressor protein for the treatment of cancer.
“Astex is applying its…
If anyone UK-based missed out on a stand at Medica and would like a 12 sq m (3mx4m) shell stand on the UK (ABHI) pavilion in Hall 16, please get in touch with Berenice.Mann@clsdiagnostics.com.
Manchester, 9th August, 2023
Kadans Science Partner has submitted a detailed planning application for a state-of-the-art life science building at Upper Brook Street. Working collectively with a consortium of partners, this significant development forms a key part of the transformative vision to deliver an exemplary new neighbourhood for the city.
The building consists of an expansive ground floor plus 7 upper floors. The lower portion of the building is oriented around a central atrium to provide informal break out zones and promote interdisciplinary collaboration. Through…
Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appointment of Dr Parisa Zamiri as its Chief Medical Officer, effective immediately. Dr. Zamiri brings with her extensive experience in biopharmaceutical and small molecule drug discovery and development, drug and device safety, pharmacovigilance, and biomarker development across various therapeutic areas.
Dr. Zamiri joins CTx from Graybug Vision, Inc., where she held the position of Chief Medical Officer and was…
Astex Expands Drug Discovery Collaboration With MSD
Cambridge, UK, 8 August 2023, Astex Pharmaceuticals (UK) (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, today announced an exclusive worldwide research collaboration and license agreement with MSD (Merck & Co., Inc., Rahway, N.J., USA). The goal of the collaboration is to identify small molecule candidates with activity towards a tumour suppressor protein for the treatment of cancer.
“Astex is applying its…
Dear One Nucleus members,
We are delighted to invite you to Collaborate and Network with your Local Community using Connexn - a new online platform to make team-building easy and intuitive. Created by Cambridge University members and alumni and free to use, Connexn allows easy connection for scientists, entrepreneurs, and creatives in Cambridge and beyond.
Make connections within the area that is right for you and get help with your hands-on project now!
Patients could benefit from bespoke cancer-fighting treatments with fewer side effects thanks to a new partnership between a biotech company and a UK university.
The University of Leicester has joined forces with Cambridge-based Isogenica to develop new immunotherapies – a process where the patient’s immune system is helped to fight cancer – which will be tested on a ‘virtual patient’.
The virtual patient will be created in the laboratory, by taking samples of a patient’s own tumour cells and immune system, and will then be presented with a range of new immunotherapies developed by the…